Crystal structure of FMN-dependent nitroreductase from Escherichia coli B:: A prodrug-activating enzyme

被引:120
作者
Parkinson, GN [1 ]
Skelly, JV [1 ]
Neidle, S [1 ]
机构
[1] Inst Canc Res, Chester Beatty Labs, CRC Biomol Struct Unit, London SW3 6JB, England
关键词
D O I
10.1021/jm000159m
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The FMN-dependent flavoprotein nitroreductase from Escherichia coli B (NTR) is used in cancer chemotherapy to activate a range of prodrugs. The crystal structure of this enzyme has been determined, using molecular replacement methods and refined at 2.06 Angstrom resolution. The recombinant 24-kDa enzyme was crystallized in the tetragonal space group P4(1)2(1)2, with unit cell dimensions of a = b = 57.74 Angstrom and c = 275.51 Angstrom and two molecules in the asymmetric unit. The structure has a final R factor of 20.3% (R-free = 26.7%), for all data between the resolution ranges of 10-2.06 Angstrom, and includes 4453 protein atoms, 230 water molecules, and 2 flavin mononucleotide (FMN) molecules. The functional unit is a homodimer, which forms the asymmetric unit in the crystal structure. The tertiary structures of these two monomers and their subunit interactions are nearly identical. The molecular replacement search model, the crystal structure of the major NAD(P)H:FMN oxidoreductase of Vibrio fisheri (FRase 1), was selected on the basis of its high sequence identity to that of NTR. The final superposition of these two enzymes revealed a very similar overall fold, with variation in the structures focused around surface loops and helices near the FMN cofactor. Helix G is implicated in substrate specificity and is better resolved in the present NTR structure than in the previously reported FRase 1 structure. The FMN binding pocket is also well-resolved, showing the presence of two channels leading into the active site. The amino acid side chains and main chain atoms interacting with the FMN are well-ordered. The structure of the substrate binding pocket has been used to examine substrate specificity and enzyme kinetics for prodrugs used in antibody-directed enzyme prodrug therapy (ADEPT) and gene-directed enzyme prodrug therapy (GDEPT).
引用
收藏
页码:3624 / 3631
页数:8
相关论文
共 26 条
[1]  
ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999
[2]   THE BIOACTIVATION OF 5-(AZIRIDIN-1-YL)-2,4-DINITROBENZAMIDE (CB1954) .1. PURIFICATION AND PROPERTIES OF A NITROREDUCTASE ENZYME FROM ESCHERICHIA-COLI - A POTENTIAL ENZYME FOR ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY (ADEPT) [J].
ANLEZARK, GM ;
MELTON, RG ;
SHERWOOD, RF ;
COLES, B ;
FRIEDLOS, F ;
KNOX, RJ .
BIOCHEMICAL PHARMACOLOGY, 1992, 44 (12) :2289-2295
[3]   BIOACTIVATION OF DINITROBENZAMIDE MUSTARDS BY AN ESCHERICHIA-COLI-B NITROREDUCTASE [J].
ANLEZARK, GM ;
MELTON, RG ;
SHERWOOD, RF ;
WILSON, WR ;
DENNY, WA ;
PALMER, BD ;
KNOX, RJ ;
FRIEDLOS, F ;
WILLIAMS, A .
BIOCHEMICAL PHARMACOLOGY, 1995, 50 (05) :609-618
[4]   The Protein Data Bank [J].
Berman, HM ;
Westbrook, J ;
Feng, Z ;
Gilliland, G ;
Bhat, TN ;
Weissig, H ;
Shindyalov, IN ;
Bourne, PE .
NUCLEIC ACIDS RESEARCH, 2000, 28 (01) :235-242
[5]   THE DIFFERENCES IN KINETICS OF RAT AND HUMAN DT DIAPHORASE RESULT IN A DIFFERENTIAL SENSITIVITY OF DERIVED CELL-LINES TO CB-1954 (5-(AZIRIDIN-1-YL)-2,4-DINITROBENZAMIDE) [J].
BOLAND, MP ;
KNOX, RJ ;
ROBERTS, JJ .
BIOCHEMICAL PHARMACOLOGY, 1991, 41 (6-7) :867-875
[6]  
BRUNGER AT, 1992, XPLOR VERSION 3 1 SY
[7]  
BRYANT C, 1991, J BIOL CHEM, V266, P4126
[8]   Mustard prodrugs for activation by Escherichia coli nitroreductase in gene-directed enzyme prodrug therapy [J].
Friedlos, F ;
Denny, WA ;
Palmer, BD ;
Springer, CJ .
JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (08) :1270-1275
[9]   CRYSTAL-STRUCTURE OF NADH OXIDASE FROM THERMUS-THERMOPHILUS [J].
HECHT, HJ ;
ERDMANN, H ;
PARK, HJ ;
SPRINZL, M ;
SCHMID, RD .
NATURE STRUCTURAL BIOLOGY, 1995, 2 (12) :1109-1114
[10]   THE BIOACTIVATION OF 5-(AZIRIDIN-1-YL)-2,4-DINITROBENZAMIDE (CB1954) .2. A COMPARISON OF AN ESCHERICHIA-COLI NITROREDUCTASE AND WALKER DT DIAPHORASE [J].
KNOX, RJ ;
FRIEDLOS, F ;
SHERWOOD, RF ;
MELTON, RG ;
ANLEZARK, GM .
BIOCHEMICAL PHARMACOLOGY, 1992, 44 (12) :2297-2301